GLMD - Galmed Pharmaceuticals Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.02
+0.02 (+0.33%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close6.00
Open6.02
Bid5.82 x 900
Ask6.64 x 1200
Day's Range6.00 - 6.05
52 Week Range3.61 - 12.22
Volume21,803
Avg. Volume38,314
Market Cap92.92M
Beta3.12
PE Ratio (TTM)N/A
EPS (TTM)-0.99
Earnings DateMay 14, 2018 - May 18, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.80
Trade prices are not sourced from all markets
  • What’s Ahead For Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)?
    Simply Wall St.14 days ago

    What’s Ahead For Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)?

    Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), a US$90.91M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and theRead More...

  • What You Must Know About Galmed Pharmaceuticals Ltd’s (NASDAQ:GLMD) Market Risks
    Simply Wall St.17 days ago

    What You Must Know About Galmed Pharmaceuticals Ltd’s (NASDAQ:GLMD) Market Risks

    For Galmed Pharmaceuticals Ltd’s (NASDAQ:GLMD) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. GLMD is exposedRead More...

  • Associated Press19 days ago

    Galmed Pharmaceuticals: 1Q Earnings Snapshot

    On a per-share basis, the Tel Aviv, Israel-based company said it had a loss of 17 cents. The biopharmaceutical company posted revenue of $268,000 in the period, which matched Street forecasts. Galmed Pharmaceuticals ...

  • PR Newswire19 days ago

    Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2018 Financial Results

    - Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST - TEL AVIV, Israel , May 9, 2018 /PRNewswire/ --Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), ...

  • Has Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Improved Earnings Growth In Recent Times?
    Simply Wall St.25 days ago

    Has Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Improved Earnings Growth In Recent Times?

    For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Galmed Pharmaceuticals Ltd’s (NASDAQ:GLMD) track record on a high level, toRead More...

  • PR Newswire27 days ago

    Galmed Pharmaceuticals to Report First Quarter 2018 Financial Results and Provide Business Update on Wednesday, May 9

    TEL AVIV, Israel , May 1, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...

  • What Are Analysts Expecting From Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Over The Next Few Years?
    Simply Wall St.last month

    What Are Analysts Expecting From Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Over The Next Few Years?

    In December 2017, Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) announced its most recent earnings update, which confirmed company earnings became less negative compared to the previous year’s level – great news forRead More...

  • PR Newswirelast month

    Galmed Pharmaceuticals to Host Post-EASL Key Opinion Leader Call on the Scientific Rationale and Clinical Development of Aramchol™ for NASH

    TEL AVIV, Israel, April 16, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, announced today that it will host a Post-European Association for the Study of the Liver ("EASL") Key Opinion Leader ("KOL") call on the Scientific Rationale and Clinical Development of Aramchol for NASH, on Monday, April 30, 2018 at 1:00pm ET. The call will feature presentations by the KOLs Scott Friedman, MD, from the Icahn School of Medicine at Mount Sinai, and Arun Sanyal, MD, from VCU Medical Center, who will provide takeaways from Galmed's presentation and scientific workshop at EASL, including a discussion on the biological heterogeneity within NASH populations and new scientific data on the mechanism by which Aramchol exerts its effect on fibrosis.  KOLs and Galmed's management team will be available to answer questions at the conclusion of the call.

  • InMed Announces Appointment of Joshua Blacher as Chief Business Officer
    CNW Group2 months ago

    InMed Announces Appointment of Joshua Blacher as Chief Business Officer

    InMed Announces Appointment of Joshua Blacher as Chief Business Officer

  • PR Newswire2 months ago

    Galmed Pharmaceuticals Announces Pricing of $6.0 Million Registered Direct Offering

    TEL AVIV, Israel, April 3, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and other liver diseases, announced today that it has entered into a securities purchase agreement with Biotechnology Value Fund, L.P. and certain of its affiliates for the purchase and sale in a registered direct offering of 1,000,000 ordinary shares and warrants to purchase 1,000,000 ordinary shares, for a purchase price of $6.00 per share and related warrant. The warrants have an exercise price of $15.00 per share and will expire one year from the date of issuance. The securities to be issued in the registered direct offering described above are being offered pursuant to a shelf registration statement on Form F-3 (File No. 333-223923) which was declared effective by the Securities and Exchange Commission ("SEC") on April 2, 2018. A prospectus supplement and accompanying base prospectus relating to the registered direct offering will be filed with the SEC. When available, copies of the prospectus supplement and the accompanying base prospectus relating to this offering may be obtained at the SEC's website at http://www.sec.gov or by contacting the Company at Attn: Investor Relations, 16 Tiomkin St., Tel Aviv 6578317, Israel or by telephone at +972-3693-8448.

  • PR Newswire2 months ago

    Galmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on Fibrosis at EASL

    TEL AVIV, Israel , March 27, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...

  • Benzinga2 months ago

    Aramchol's Failed Past Isn't Its Future; Galmed Gets An Upgrade

    Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) lost a bull in February on Aramchol’s failed ARRIVE study for HIV-related fatty liver disease. However, the drug is now generating optimism for distinct indications. ...

  • Associated Press2 months ago

    Galmed Pharmaceuticals reports 4Q loss

    The Tel Aviv, Israel-based company said it had a loss of 27 cents per share. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • PR Newswire2 months ago

    Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

    Conference Call and Webcast Today at 8:30 a.m. EDT / 5:30 a.m. PDT TEL AVIV, Israel , March 13, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), ...

  • ACCESSWIRE2 months ago

    Galmed Pharmaceuticals Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 13, 2018 / Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 13, 2018, at 8:30 AM Eastern ...

  • PR Newswire3 months ago

    Galmed Pharmaceuticals to Report Full Year and Fourth Quarter 2017 Financial Results and Provide Business Update on Tuesday, March 13

    TEL AVIV, Israel , March 5, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...

  • PR Newswire3 months ago

    Galmed Pharmaceuticals to Participate in Investor Conferences in March

    TEL AVIV, Israel , Mar. 2, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmedˮ or the "Companyˮ), a clinical-stage biopharmaceutical company focused on the development of ...

  • Galmed Pharmaceuticals Ltd’s (NASDAQ:GLMD) Path To Profitability
    Simply Wall St.3 months ago

    Galmed Pharmaceuticals Ltd’s (NASDAQ:GLMD) Path To Profitability

    Galmed Pharmaceuticals Ltd’s (NASDAQ:GLMD): Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The US$70.54M market-cap company’s loss lessens sinceRead More...

  • PR Newswire3 months ago

    Galmed Announces ARRIVE Study Data

    ARRIVE, a Phase IIa, investigator initiated clinical trial conducted at the University of California San Diego by Professor Rohit Loomba was a randomized, double-blinded, placebo-controlled, 12 weeks, proof-of-concept study that evaluated the safety and efficacy of Aramchol™ at 600mg/day versus placebo in 50 patients with HIV-associated lipodystrophy and non-alcoholic fatty liver disease, or NAFLD. The primary endpoint of the study was improvement of liver fat at 12 weeks, as measured by MRI-PDFF.

  • PR Newswire4 months ago

    Galmed Pharmaceuticals to Provide Corporate Update at the LEERINK Partners 7th Annual Global Healthcare Conference

    TEL AVIV, Israel, Feb. 8, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmedˮ or the "Companyˮ), a clinical-stage biopharmaceutical company focused on the development of Aramchol[TM], a once-daily, oral therapy, liver targeted SCD1 modulator, for the treatment of NASH, today announced that its senior management will provide an overview of the scientific rationale and clinical development of Aramchol™, at the LEERINK Partners 7th Annual Global Healthcare Conference.

  • PR Newswire4 months ago

    Galmed Granted "Preferred Technological Enterprise" Status Which may Provide the Company With Significant Financial Benefits

    TEL AVIV, Israel, Feb. 7, 2018 /PRNewswire/ -- Galmed Pharmaceuticals, Ltd. (GLMD), ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and other liver diseases, today announced that the Israeli Tax Authority has issued a tax ruling granting Galmed Research and Development Ltd. (a wholly owned subsidiary of the Company, owner of all of Galmed's IP) ("Galmed R&D") "Preferred Technological Enterprise" status, subject to the conditions and terms of the tax ruling. The grant of the status means that Galmed R&D will be subject to a reduced Israeli corporate tax rate that will range between 6%-12% on any future taxable "technological income" which includes sales, licenses and royalties from its IP protected products.

  • Which Gilead Sciences Portfolio Could Give a Long-Term Boost
    Market Realist4 months ago

    Which Gilead Sciences Portfolio Could Give a Long-Term Boost

    Where's Gilead Sciences Now? Key January Updates

  • PR Newswire5 months ago

    Galmed Pharmaceuticals Raised Gross Proceeds of $11.6 Million Under ATM Programs During December 2017

    TEL AVIV, Israel, Jan. 2, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, and other liver diseases, today announced it raised approximately $11.6 million in gross proceeds during December 2017 under the Company's at-the-market ("ATM") programs.  The Company issued 1,368,667 ordinary shares under its former and existing ATM programs during December 2017 at an average sale price of $8.45 per share. This amount includes gross proceeds of approximately $6.0 million under the Company's existing ATM program that wasestablished on December 22, 2017.

  • Benzinga5 months ago

    7 Stocks Moving In Tuesday's After-Hours Session

    Gainers: Energous Corp (NASDAQ: WATT ) shares are surging up over 74 percent after reports that the company received FCC certification for over-the-air, power-at-a-distance wireless charging. HTG Molecular ...